Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...

I n a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...

Coupled with the invalidation of 10x Genomics’ 10,155,981 patent last year, Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse’s ...

10x Genomics, which belongs to the Zacks Medical Info Systems industry, posted revenues of $153.1 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.46%. This ...

"The entire department that I work with consist of very intelligent individuals that are great at their job. The best part is that every person in my department is kind and willing to teach me and ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.